Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 On 19thDecember 2014
Summary The industry analysis specialist, has released its new report, “Leiomyosarcoma Therapeutics Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global Leiomyosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Leiomyosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Leiomyosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-leiomyosarcoma-therapeutics-pipeline-assessment-and-marketforecasts-135241 Scope The report provides information on the key drivers and challenges of the Leiomyosarcoma Therapeutics market. Its scope includes Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Leiomyosarcoma Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Leiomyosarcoma Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Leiomyosarcoma Therapeutics market. - Analysis of key recent licensing and partnership agreements in Leiomyosarcoma Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Leiomyosarcoma Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Leiomyosarcoma Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- What’s the next big thing in the global Leiomyosarcoma Therapeutics market landscape? – Identify, understand and capitalize.
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Leiomyosarcoma Therapeutics - Introduction 2.1 Disease Overview 2.2 Epidemiology 2.3 Etiology and Risk Factors 2.4 Symptoms 2.5 Diagnosis 2.5.1 Imaging of the affected area and likely areas to be affected 2.5.2 Procedures 2.5.3 Laboratory studies 2.6 Staging of Leiomyosarcoma 2.7 Treatment 2.7.1 Surgery 2.7.2 Radiation Therapy 2.7.3 Chemotherapy 2.8 GlobalData Pipeline Report Guidance Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
3 Leiomyosarcoma Therapeutics - Market Characterization 3.1 Leiomyosarcoma Therapeutics Major Markets, Market Size (2006-2011) - Global 3.2 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Global 3.3 Leiomyosarcoma Therapeutics Market Size (2006-2011) - The US 3.4 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - The US 3.5 Leiomyosarcoma Therapeutics Market Size (2006-2011) - The UK 3.6 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - The UK 3.7 Leiomyosarcoma Therapeutics Market Size (2006-2011) - France 3.8 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - France 3.9 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Germany 3.10 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Germany 3.11 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Italy 3.12 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Italy 3.13 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Spain 3.14 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Spain 3.15 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Japan 3.16 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Japan 3.17 Drivers and Barriers for the Leiomyosarcoma Therapeutics Market 3.17.1 Drivers for the Leiomyosarcoma Therapeutics Market 3.17.2 Barriers for the Leiomyosarcoma Therapeutics Market 3.18 Opportunity and Unmet Need Analysis 3.19 Key Takeaway 4 Leiomyosarcoma Therapeutics - Competitor Assessment 4.1 Overview 4.1.1 Strategic Competitor Assessment 4.2 Key Takeaway 5 Leiomyosarcoma Therapeutics - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.2.1 Leiomyosarcoma Therapeutics - Pre-registration Pipeline 5.2.2 Leiomyosarcoma Therapeutics - Phase III Pipeline 5.2.3 Leiomyosarcoma Therapeutics - Phase II Pipeline 5.2.4 Leiomyosarcoma Therapeutics - Phase I Pipeline 5.3 Leiomyosarcoma Therapeutics - Clinical Pipeline by Mechanism of Action 5.3.1 Leiomyosarcoma Therapeutics - Other Mechanisms of Action 5.4 Leiomyosarcoma Technology Trends Analytical Framework 5.5 Leiomyosarcoma Therapeutics - Promising Drugs under Clinical Development 5.6 Profiles of Key Late Stage Drugs under Clinical Development 5.6.1 Ridaforolimus Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.6.2 TH-302 5.6.3 Votrient (pazopanib) 5.6.4 Yondelis (trabectedin) 5.6.5 Halaven (eribulin mesylate) 5.7 Key takeaway 6 Leiomyosarcoma Therapeutics - Clinical Trials Mapping 6.1 Clinical Trials by Phase 6.2 Clinical Trials by Trial Status 6.3 Clinical Trials by Overall Sponsors 6.4 Clinical Trials by Prominent Sponsors 6.5 Top Companies Participating in Therapeutics Clinical Trials 7 Leiomyosarcoma Therapeutics - Strategic Assessment 7.1 Implications for Future Market Competition 8 Leiomyosarcoma Therapeutics - Future Players 8.1 Introduction 8.2 Company Profiles 8.2.1 Ariad Pharmaceuticals 8.2.2 Merck & Co. Inc. 8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C 8.2.4 PharmaMar S.A. 8.2.5 Threshold Pharmaceuticals 8.2.6 GlaxoSmithKline 8.2.7 Eisai Co., Ltd. 8.3 Other Companies in the Leiomyosarcoma Market, 2011 8.3.1 Leiomyosarcoma Therapeutics - Other Future Players 9 Leiomyosarcoma Therapeutics - Appendix 9.1 Market Definitions 9.2 Abbreviations 9.3 Methodology 9.3.1 Coverage 9.3.2 Secondary Research 9.3.3 Forecasting 9.3.4 Primary Research 9.3.5 Expert Panel Validation 9.4 Contact Us 9.5 Disclaimer 9.6 Bibliography
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
List Of Tables Table 1: Types of Leiomyosarcomas Table 2: American Joint Committee on Cancer (AJCC) Staging System Table 3: Musculoskeletal Tumor Society (MSTS) Staging System Table 4: Leiomyosarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 Table 5: Leiomyosarcoma Therapeutics Market, Global, Forecast ($m), 2011-2019 Table 6: Leiomyosarcoma Therapeutics Market, The US, Revenue ($m), 2006-2011 Table 7: Leiomyosarcoma Therapeutics Market, The US, Forecast ($m), 2011-2019 Table 8: Leiomyosarcoma Therapeutics Market, The UK, Revenue ($m), 2006-2011 Table 9: Leiomyosarcoma Therapeutics Market, The UK, Forecast ($m), 2011-2019 Table 10: Leiomyosarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 Table 11: Leiomyosarcoma Therapeutics Market, France, Forecast ($m), 2011-2019 Table 12: Leiomyosarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 Table 13: Leiomyosarcoma Therapeutics Market, Germany, Forecast ($m), 2011-2019 Table 14: Leiomyosarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 Table 15: Leiomyosarcoma Therapeutics Market, Italy, Forecast ($m), 2011-2019 Table 16: Leiomyosarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 Table 17: Leiomyosarcoma Therapeutics Market, Spain, Forecast ($m), 2011-2019 Table 18: Leiomyosarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 Table 19: Leiomyosarcoma Therapeutics Market, Japan, Forecast ($m), 2011-2019 Table 20: Leiomyosarcoma Therapeutics - Pre-registration Pipeline, 2011 Table 21: Leiomyosarcoma Therapeutics - Phase III Pipeline, 2011 Table 22: Leiomyosarcoma Therapeutics - Phase II Pipeline, 2011 Table 23: Leiomyosarcoma Therapeutics - Phase I, 2011 Table 24: Leiomyosarcoma Therapeutics, Other Mechanisms of Action from Figure Table 25: Leiomyosarcoma Therapeutics - Promising Drugs Under Clinical Development, 2011 Table 26: Patient Characteristics in SUCCEED Trial Table 27: PFS Observed in SUCCEED Trial Table 28: Adverse Events Observed During SUCCEED Trial Table 29: Adverse Events Observed with the Class of mTOR Inhibitors Table 30: Responses Shown by Soft Tissue Sarcoma Group in TH-302 Phase II Study Table 31: Adverse Events of TH-302 Table 32: Hematologic Toxicity Shown by TH-302 Table 33: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Country, 2011 Table 34: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Phase, 2011 Table 35: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Status, 2011 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 36: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Overall Sponsors, 2011 Table 37: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Prominent Sponsors, 2011 Table 38: Leiomyosarcoma Therapeutics, Top Companies Participating in Clinical Trials, 2011 Table 39: Ariad Pharmaceuticals, Leiomyosarcoma Pipeline Product, 2011 Table 40: Merck & Co., Leiomyosarcoma Pipeline Product, 2011 Table 41: Threshold Pharmaceuticals Inc., Leiomyosarcoma Pipeline Product, 2011 Table 42: GlaxoSmithKline, Leiomyosarcoma Pipeline Product, 2011 Table 43: Eisai Co., Ltd., Leiomyosarcoma Pipeline Product, 2011
List Of Figures Figure 1: Leiomyosarcomas at Different Locations in the Body Figure 2: Treatment Algorithm for Leiomyosarcoma Figure 3: Leiomyosarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 Figure 4: Leiomyosarcoma Therapeutics Major Market Share , 2011 Figure 5: Leiomyosarcoma Therapeutics Market, Global, Forecast ($m), 2011-2019 Figure 6: Leiomyosarcoma Therapeutics Major Market Share ($m), 2019 Figure 7: Leiomyosarcoma Therapeutics Market, The US, Revenue ($m), 2006-2011 Figure 8: Leiomyosarcoma Therapeutics Market, The US, Forecast ($m), 2011-2019 Figure 9: Leiomyosarcoma Therapeutics Market, The UK, Revenue ($m), 2006-2011 Figure 10: Leiomyosarcoma Therapeutics Market, The UK, Forecast ($m), 2011-2019 Figure 11: Leiomyosarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 Figure 12: Leiomyosarcoma Therapeutics Market, France, Forecast ($m), 2011-2019 Figure 13: Leiomyosarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 Figure 14: Leiomyosarcoma Therapeutics Market, Germany, Forecast ($m), 2011-2019 Figure 15: Leiomyosarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 Figure 16: Leiomyosarcoma Therapeutics Market, Italy, Forecast ($m), 2011-2019 Figure 17: Leiomyosarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 Figure 18: Leiomyosarcoma Therapeutics Market, Spain, Forecast ($m), 2011-2019 Figure 19: Leiomyosarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 Figure 20: Leiomyosarcoma Therapeutics Market, Japan, Forecast ($m), 2011-2019 Figure 21: Drivers and Barriers for Leiomyosarcoma Therapeutics, 2011 Figure 22: Opportunity and Unmet Need in the Leiomyosarcoma Therapeutics Market, 2011 Figure 23: Leiomyosarcoma Therapeutics, Strategic Competitor Assessment, 2011 Figure 24: Leiomyosarcoma Therapeutics - Pipeline by Phase of Development, 2011 Figure 25: Leiomyosarcoma Therapeutics, Pipeline by Mechanism of Action (%), 2011 Figure 26: Technology Trends Analytical Framework of the Leiomyosarcoma Pipeline, 2011 Figure 27: Technology Trends Analytical Framework of Leiomyosarcoma Pipeline - Description, Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2011 Figure 28: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Country, 2011 Figure 29: Leiomyosarcoma Therapeutics, Clinical Trials by Phase (%), 2011 Figure 30: Leiomyosarcoma Therapeutics, Clinical Trials by Status (%), 2011 Figure 31: Leiomyosarcoma Therapeutics, Clinical Trials by Overall Sponsors (%), 2011 Figure 32: Leiomyosarcoma Therapeutics, Clinical Trials by Prominent Sponsors (%), 2011 Figure 33: Leiomyosarcoma Therapeutics, Companies Participating in Therapeutic Clinical Trials, 2011 Figure 34: Implications for Future Market Competition in Leiomyosarcoma Therapeutic Market, 2011 Figure 35: Leiomyosarcoma Therapeutics, Number of Pipeline Molecules by Company, 2011 Figure 36: GlobalData Market Forecasting Model
Report Price: Licence Type
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Related Reports: Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018 Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Hepatic Encephalopathy - Pipeline Assessment and Market Forecasts to 2019 Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Gauchers Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Sarcoidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Pompe Disease (GAA Deficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-leiomyosarcomatherapeutics-pipeline-assessment-and-market-forecasts-135241
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/